SARS-CoV-2 nucleocapsid : Biological functions and implication for disease diagnosis and vaccine design
© 2023 John Wiley & Sons Ltd..
The coronavirus disease 2019 (COVID-19) pandemic is transmitted by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has affected millions of people all around the world, leading to more than 6.5 million deaths. The nucleocapsid (N) phosphoprotein plays important roles in modulating viral replication and transcription, virus-infected cell cycle progression, apoptosis, and regulation of host innate immunity. As an immunodominant protein, N protein induces strong humoral and cellular immune responses in COVID-19 patients, making it a key marker for studying N-specific B cell and T cell responses and the development of diagnostic serological assays and efficient vaccines. In this review, we focus on the structural and functional features and the kinetic and epitope mapping of B cell and T cell responses against SARS-CoV-2 N protein to extend our understanding on the development of sensitive and specific diagnostic immunological tests and effective vaccines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Reviews in medical virology - 33(2023), 3 vom: 01. Mai, Seite e2431 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maghsood, Faezeh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 08.05.2023 Date Revised 08.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/rmv.2431 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352973803 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352973803 | ||
| 003 | DE-627 | ||
| 005 | 20231226054933.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/rmv.2431 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1176.xml |
| 035 | |a (DE-627)NLM352973803 | ||
| 035 | |a (NLM)36790816 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maghsood, Faezeh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 nucleocapsid |b Biological functions and implication for disease diagnosis and vaccine design |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.05.2023 | ||
| 500 | |a Date Revised 08.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 John Wiley & Sons Ltd. | ||
| 520 | |a The coronavirus disease 2019 (COVID-19) pandemic is transmitted by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has affected millions of people all around the world, leading to more than 6.5 million deaths. The nucleocapsid (N) phosphoprotein plays important roles in modulating viral replication and transcription, virus-infected cell cycle progression, apoptosis, and regulation of host innate immunity. As an immunodominant protein, N protein induces strong humoral and cellular immune responses in COVID-19 patients, making it a key marker for studying N-specific B cell and T cell responses and the development of diagnostic serological assays and efficient vaccines. In this review, we focus on the structural and functional features and the kinetic and epitope mapping of B cell and T cell responses against SARS-CoV-2 N protein to extend our understanding on the development of sensitive and specific diagnostic immunological tests and effective vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a diagnosis | |
| 650 | 4 | |a epitope mapping | |
| 650 | 4 | |a nucleocapsid | |
| 650 | 4 | |a vaccine | |
| 650 | 7 | |a Nucleocapsid Proteins |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Ghorbani, Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Yadegari, Hamidreza |e verfasserin |4 aut | |
| 700 | 1 | |a Golsaz-Shirazi, Forough |e verfasserin |4 aut | |
| 700 | 1 | |a Amiri, Mohammad Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Shokri, Fazel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Reviews in medical virology |d 1996 |g 33(2023), 3 vom: 01. Mai, Seite e2431 |w (DE-627)NLM090684788 |x 1099-1654 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2023 |g number:3 |g day:01 |g month:05 |g pages:e2431 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/rmv.2431 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2023 |e 3 |b 01 |c 05 |h e2431 | ||